Aasmundstad T A, Haugen O A
Department of Pathology, Regionsykehuset, University of Trondheim, Norway.
Eur J Cancer. 1990;26(9):956-9. doi: 10.1016/0277-5379(90)90619-5.
Cellular DNA-ploidy in 74 clinically detected intraductal breast carcinomas (IDCs) was analysed by flow cytometry. The histograms were classified as either diploid or aneuploid, and the DNA ploidy pattern compared with that of invasive breast carcinomas and normal breast tissue. All normal breast tissues were diploid while 28 (38%) of the IDCs were aneuploid, the DNA indices ranging from 1.32 to 2.00. The frequency of aneuploidy in invasive ductal carcinomas (73%) was significantly higher (P = 0.003), DNA index ranging from 1.34 to 2.92, compared with that in IDCs. Retrospectively, 14.5% of the patients had invasive breast cancer 16-166 months after the diagnosis of IDC. Neither DNA ploidy nor histopathological classification alone predicted clinical outcome, but patients with DNA diploid non-comedo IDC had a more favourable course.
采用流式细胞术分析了74例临床检测的乳腺导管内癌（IDC）的细胞DNA倍体。将直方图分为二倍体或非整倍体，并将DNA倍体模式与浸润性乳腺癌和正常乳腺组织的模式进行比较。所有正常乳腺组织均为二倍体，而28例（38%）IDC为非整倍体，DNA指数范围为1.32至2.00。与IDC相比，浸润性导管癌的非整倍体频率（73%）显著更高（P = 0.003），DNA指数范围为1.34至2.92。回顾性分析显示，14.5%的患者在IDC诊断后16 - 166个月发生浸润性乳腺癌。单独的DNA倍体或组织病理学分类均不能预测临床结局，但DNA二倍体非粉刺型IDC患者的病程更有利。
